Tarsus Pharmaceuticals Q2 2024 Earnings Report $53.34 +0.08 (+0.15%) (As of 10:21 AM ET) Earnings HistoryForecast Tarsus Pharmaceuticals EPS ResultsActual EPS-$0.88Consensus EPS -$0.98Beat/MissBeat by +$0.10One Year Ago EPS-$1.17Tarsus Pharmaceuticals Revenue ResultsActual Revenue$40.81 millionExpected Revenue$31.30 millionBeat/MissBeat by +$9.51 millionYoY Revenue GrowthN/ATarsus Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/8/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseTARS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Forced out of retirement by these trades (Ad)You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedMake sure to check out Gamma Pockets HERE while it’s still widely available Tarsus Pharmaceuticals Earnings HeadlinesTarsus Pharmaceuticals: Early Rollout Exceeding ExpectationsDecember 10, 2024 | seekingalpha.comTarsus Pharmaceuticals' SWOT analysis: XDEMVY success drives stock outlookNovember 27, 2024 | uk.investing.comWill the Nasdaq 100 crash?In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!December 18, 2024 | DTI (Ad)Finding Winners In Biotech, Probably The Riskiest SectorNovember 26, 2024 | seekingalpha.comTarsus PharmaceuticalsNovember 19, 2024 | forbes.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comSee More Tarsus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tarsus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tarsus Pharmaceuticals and other key companies, straight to your email. Email Address About Tarsus PharmaceuticalsTarsus Pharmaceuticals (NASDAQ:TARS), a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.View Tarsus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
